Inhibitory effects of catalpol on DNCB-induced atopic dermatitis and IgE-mediated mast cells reaction

Int Immunopharmacol. 2024 Jan 5:126:111274. doi: 10.1016/j.intimp.2023.111274. Epub 2023 Dec 4.

Abstract

Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease driven by immune dysregulation. Catalpol is an iridoids, possessing anti-inflammatory, antioxidant, and neuroprotective activities. It can be added to food as a dietary supplement. To evaluate the effects and mechanisms of catalpol on AD, both in vitro and in vivo studies were conducted. It was found that catalpol downregulated the phosphorylation of Lyn and Syk to inhibit various downstream pathways, including intracellular Ca2+ elevation, cytokines generation, and histamine release, which ultimately controlled mast cell (MCs) degranulation. The results showed that catalpol alleviated AD-like skin lesions and MC infiltration via regulation of pro-Th2 and Th2 cytokines in vivo. Furthermore, this compound reduced the levels of IgE in AD mice and improved allergic reactions in PCA mice. The results provided that catalpol was potentially developed as a dietary supplement to improve AD and other atopic diseases.

Keywords: Atopic dermatitis; Catalpol; Mast cell; Passive cutaneous anaphylaxis.

MeSH terms

  • Animals
  • Cytokines / metabolism
  • Dermatitis, Atopic* / chemically induced
  • Dermatitis, Atopic* / drug therapy
  • Dinitrochlorobenzene
  • Immunoglobulin E / metabolism
  • Mast Cells
  • Mice
  • Mice, Inbred BALB C
  • Skin

Substances

  • catalpol
  • Dinitrochlorobenzene
  • Immunoglobulin E
  • Cytokines